Cladribine plus low-dose cytarabine and decitabine for AML or MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML or high-risk MDS, either newly diagnosed, or in relapse/refractory depending on the study group
- Your cancer risk level must fit the study group (for new cases: about 10%+ blasts or higher-risk scores; for relapsed: already had at least one AML treatment)
- Your age must match the group (at least 60 for one newly diagnosed group; at least 18 for the others)
- Your body must handle treatment: blood tests for liver and kidney function must meet limits
- Your general health/activity level must be limited enough (ECOG 2 or less in some groups)
- If you can become pregnant: you must use effective birth control and have a negative pregnancy test; pregnancy and breastfeeding are not allowed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral (by mouth) form of the chemotherapy drug cladribine, taken daily, for people with AML. It aims to find a safe and effective dose and see how well it controls the leukemia.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.